Compass Therapeutics, Inc.
CMPX
$1.97
$0.105.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 0.00 | 850.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 0.00 | 850.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 0.00 | 0.00 | 850.00K |
| SG&A Expenses | 18.87M | 16.87M | 16.09M | 16.73M | 16.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.17M | 72.84M | 71.42M | 67.85M | 62.67M |
| Operating Income | -75.17M | -72.84M | -71.42M | -67.85M | -61.82M |
| Income Before Tax | -68.17M | -66.49M | -65.81M | -62.03M | -55.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.17 | -66.49 | -65.81 | -62.03 | -55.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.17M | -66.49M | -65.81M | -62.03M | -55.22M |
| EBIT | -75.17M | -72.84M | -71.42M | -67.85M | -61.82M |
| EBITDA | -75.02M | -72.56M | -71.02M | -67.32M | -61.25M |
| EPS Basic | -0.41 | -0.43 | -0.46 | -0.45 | -0.40 |
| Normalized Basic EPS | -0.26 | -0.27 | -0.29 | -0.28 | -0.25 |
| EPS Diluted | -0.41 | -0.43 | -0.46 | -0.45 | -0.40 |
| Normalized Diluted EPS | -0.26 | -0.27 | -0.29 | -0.28 | -0.25 |
| Average Basic Shares Outstanding | 678.31M | 630.14M | 581.93M | 550.73M | 550.04M |
| Average Diluted Shares Outstanding | 678.31M | 630.14M | 581.93M | 550.73M | 550.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |